14 WiSys Technologies in "Analytical Instrumentation" or "Pharmaceuticals & Vitamin D"
WiSys is seeking a strategic partner skilled in the development and manufacturing of membranes used for the separation and/or detection of biologic molecules in solution. There is additional interest in a partner with the expertise to identify and test novel applications for these nanomembranes.
WiSys is seeking strategic partners interested in further developing this portable water quality measuring technology for application-specific or broader based commercialization.
WiSys is seeking strategic partners for field testing of this novel device, as well as for development for mass manufacturing, followed by marketing, sales, and distribution.
WiSys Technology Foundation is currently seeking a strategic industry partner to assist in the further development of its lead compound, A11, and related analogues providing a route to market for their use as novel skin whitening/lightening agents.The competitive advantage of these compounds over existing agents on the market is that they produce long-acting and reversible skin lightening with no toxicity.
WiSys Technology Foundation is seeking a strategic partner that markets or manufactures SPR instruments and is interested in co-development and/or collaboration.There is also interest in collaborating with a partner with expertise in microfluidics in order to further improve the existing sample handling system.
WiSys Technology Foundation is seeking a strategic partner to further develop, manufacture, market, and distribute a high accuracy rotary (angle) encoder. This device has the advantages of high single-reading accuracy (±0.1 arc seconds) and high average reading sensitivity (0.001 arc seconds), low production cost, compact design, and low power consumption. Possible applications include but are not limited to astronomical telescope mounts, land surveillance tools, industrial inspection and calibration, machine tools, medical devices, as well as robotics.
The WiSys Technology Foundation is seeking commercial partners interested in developing anxiolytic and anticonvulsant benzodiazepines that offer little or no side effects.